Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome
Lynch Syndrome significantly increases the lifetime risk of developing multiple cancers, including colorectal and endometrial
NOUS-209, an off-the-shelf immunotherapy vaccine created by Nouscom, trains the immune system to recognize and eliminate precancerous and cancerous cells
This Phase Ib/II study revealed durable immune responses, tumor-targeting activity and early evidence of cancer interception
HOUSTON, JANUARY 16th, 2026...
Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer
Researchers found that the amount, and not the type, of bacteria inside tumors can predict response to treatment in lab...
Immunotherapy before and after surgery improved outcomes in lung cancer patients with lymph node metastases
Perioperative nivolumab plus neoadjuvant chemotherapy improved outcomes for patients regardless of...